382 related articles for article (PubMed ID: 17955251)
1. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
2. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
3. Bisphosphonates and atrial fibrillation.
Prescrire Int; 2008 Aug; 17(96):161. PubMed ID: 19492493
[No Abstract] [Full Text] [Related]
4. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
5. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
7. [Treating with what? Therapy for how long?].
MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
[No Abstract] [Full Text] [Related]
8. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
9. Yearly zoledronic acid in postmenopausal osteoporosis.
Karam R; Camm J; McClung M
N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
[No Abstract] [Full Text] [Related]
10. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
11. Alendronate and atrial fibrillation.
Cummings SR; Schwartz AV; Black DM
N Engl J Med; 2007 May; 356(18):1895-6. PubMed ID: 17476024
[No Abstract] [Full Text] [Related]
12. [Diphosphonate therapy and osteonecrosis of the jaw].
Løkken P; Skoglund LA; Skjelbred P
Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
[No Abstract] [Full Text] [Related]
13. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
[No Abstract] [Full Text] [Related]
14. Yearly zoledronic acid in postmenopausal osteoporosis.
de Nijs RN; Westgeest AA
N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
[No Abstract] [Full Text] [Related]
15. Going on a drug holiday?
Bonnick SL
J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
[No Abstract] [Full Text] [Related]
16. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
[No Abstract] [Full Text] [Related]
17. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
Atik OS
Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
[No Abstract] [Full Text] [Related]
18. [Inflammation of the jaws during treatment with bisphosphonates].
Bartl R
Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
[No Abstract] [Full Text] [Related]
19. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
Konsta M; Bournia VK; Dania V; Iliopoulos A
J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
[No Abstract] [Full Text] [Related]
[Next] [New Search]
